GlassScriptPhysician profile
April Renee Morrison
NPI 1194759456
$1,737.96
in general payments reported to CMS, 2019-2025
15 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $61.64 · 2021: $183 · 2022: $218 · 2023: $326 · 2024: $403 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $620.85 | 2019-2025 | Veklury |
| Viiv Healthcare Company | $398.30 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Abbvie INC. | $198.35 | 2019-2025 | |
| Janssen Products, LP | $130.49 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $113.32 | 2019-2023 | Pifeltro, Delstrigo, Lagevrio |
| Astellas Pharma US INC | $51.64 | 2019 | |
| Insmed, INC. | $39.18 | 2022-2023 | Arikayce |
| Janssen Biotech, INC. | $36.71 | 2019-2023 | Symtuza |
| Napo Pharmaceuticals INC | $31.84 | 2025 | Mytesi |
| Mayne Pharma Commercial LLC | $29.35 | 2022 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| La Jolla Pharmaceutical Company | $19.03 | 2024 | Xacduro |
| Nabriva Therapeutics, Plc | $14.35 | 2020 | |
| Emd Serono, INC. | $13.66 | 2019 | |
| Paratek Pharmaceuticals, INC. | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.